Detalhe da pesquisa
1.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Lancet Oncol
; 18(9): 1202-1210, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28729151
2.
Systems analysis identifies miR-29b regulation of invasiveness in melanoma.
Mol Cancer
; 15(1): 72, 2016 11 16.
Artigo
Inglês
| MEDLINE | ID: mdl-27852308
3.
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Int J Cancer
; 136(6): E590-601, 2015 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-25081390
4.
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Clin Cancer Res
; 27(19): 5280-5288, 2021 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34210681
5.
Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma.
Cancer Immunol Res
; 8(8): 990-1003, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32580941
6.
Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.
Cancer Immunol Res
; 8(10): 1322-1334, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32938616
7.
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Clin Cancer Res
; 26(19): 5086-5091, 2020 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32605909
8.
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.
J Immunother Cancer
; 8(1)2020 04.
Artigo
Inglês
| MEDLINE | ID: mdl-32317292
9.
Predicting clinical outcome through molecular profiling in stage III melanoma.
Clin Cancer Res
; 14(16): 5173-80, 2008 Aug 15.
Artigo
Inglês
| MEDLINE | ID: mdl-18698035
10.
ECSA/DPPA2 is an embryo-cancer antigen that is coexpressed with cancer-testis antigens in non-small cell lung cancer.
Clin Cancer Res
; 14(11): 3291-8, 2008 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-18519755
11.
Desmoplastic melanoma: comparison of expression of differentiation antigens and cancer testis antigens.
Melanoma Res
; 16(4): 347-55, 2006 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-16845331
12.
A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake.
Clin Cancer Res
; 11(13): 4810-7, 2005 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16000578
13.
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Clin Cancer Res
; 11(13): 4818-26, 2005 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-16000579
14.
Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic Activity.
Cancer Immunol Res
; 4(6): 552-61, 2016 06.
Artigo
Inglês
| MEDLINE | ID: mdl-27045022
15.
Impact of 2-deoxy-2[F-18]fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma.
Mol Imaging Biol
; 7(4): 304-8, 2005.
Artigo
Inglês
| MEDLINE | ID: mdl-16041590
16.
The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.
Oncoimmunology
; 3(7): e946367, 2014.
Artigo
Inglês
| MEDLINE | ID: mdl-25610732
17.
A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.
Melanoma Res
; 24(2): 144-9, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24463460
18.
MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
Cancer Immunol Res
; 2(4): 351-60, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24764582
19.
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Clin Cancer Res
; 19(17): 4589-98, 2013 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23833303
20.
Human perforin mutations and susceptibility to multiple primary cancers.
Oncoimmunology
; 2(4): e24185, 2013 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-23734337